Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors.

Marceau F, Bachelard H, Rivard GÉ, Hébert J.

BMC Res Notes. 2019 May 27;12(1):291. doi: 10.1186/s13104-019-4335-8.

2.

Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency.

Charest-Morin X, Hébert J, Rivard GÉ, Bonnefoy A, Wagner E, Marceau F.

Front Immunol. 2018 Oct 2;9:2183. doi: 10.3389/fimmu.2018.02183. eCollection 2018.

3.

Reprint of: Editorial: Correspondence from Chirumbolo and Bjorklund.

Marceau F.

Int Immunopharmacol. 2018 Sep;62:334. doi: 10.1016/j.intimp.2018.06.038. Epub 2018 Jul 7. No abstract available.

PMID:
30089604
4.

Bifunctional ligands of the bradykinin B2 and B1 receptors: An exercise in peptide hormone plasticity.

Marceau F, Bawolak MT, Fortin JP, Morissette G, Roy C, Bachelard H, Gera L, Charest-Morin X.

Peptides. 2018 Jul;105:37-50. doi: 10.1016/j.peptides.2018.05.007. Epub 2018 May 23. Review.

PMID:
29802875
5.

D-Arg0-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B2 Receptor Agonist Metabolically Activated by Carboxypeptidases.

Bachelard H, Charest-Morin X, Marceau F.

Front Pharmacol. 2018 Mar 27;9:273. doi: 10.3389/fphar.2018.00273. eCollection 2018.

6.

Bifunctional fusion proteins containing the sequence of the bradykinin homologue maximakinin: activities at the rat bradykinin B2 receptor.

Charest-Morin X, Lodge R, Marceau F.

Can J Physiol Pharmacol. 2018 May;96(5):459-470. doi: 10.1139/cjpp-2017-0692. Epub 2018 Feb 7.

PMID:
29414245
7.

Editorial: Correspondence from Chirumbolo and Bjorklund.

Marceau F.

Int Immunopharmacol. 2018 Feb;55:A1. doi: 10.1016/j.intimp.2017.12.032. Epub 2018 Jan 6. No abstract available.

PMID:
29310999
8.

Production and evaluation of parathyroid hormone receptor1 ligands with intrinsic or assembled peroxidase domains.

Charest-Morin X, Poubelle PE, Marceau F.

Sci Rep. 2017 Oct 12;7(1):13099. doi: 10.1038/s41598-017-13548-0.

9.

S100A9 potentiates the activation of neutrophils by the etiological agent of gout, monosodium urate crystals.

Rousseau LS, Paré G, Lachhab A, Naccache PH, Marceau F, Tessier P, Pelletier M, Fernandes M.

J Leukoc Biol. 2017 Sep;102(3):805-813. doi: 10.1189/jlb.3MA0117-020R. Epub 2017 May 26.

PMID:
28550118
10.

Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B2 receptor and peptidase resistance in rats.

Charest-Morin X, Bachelard H, Jean M, Marceau F.

PeerJ. 2017 Jan 18;5:e2911. doi: 10.7717/peerj.2911. eCollection 2017.

11.
12.

Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.

Parks A, Marceau F.

Toxicol Appl Pharmacol. 2016 Aug 15;305:55-65. doi: 10.1016/j.taap.2016.06.006. Epub 2016 Jun 8.

13.

The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents.

Jean M, Raghavan A, Charles ML, Robbins MS, Wagner E, Rivard GÉ, Charest-Morin X, Marceau F.

Life Sci. 2016 Jun 15;155:180-8. doi: 10.1016/j.lfs.2016.05.010. Epub 2016 May 7.

14.

Introduction: Natural product-based drug discovery in Immunopharmacology.

Abe F, Marceau F, Talmadge JE.

Int Immunopharmacol. 2016 Aug;37:1-2. doi: 10.1016/j.intimp.2016.01.017. Epub 2016 Mar 15. No abstract available.

PMID:
26987504
15.

Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor.

Charest-Morin X, Marceau F.

PLoS One. 2016 Feb 4;11(2):e0148246. doi: 10.1371/journal.pone.0148246. eCollection 2016.

16.

In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H.

Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.

17.

Editorial: Improving the data reproducibility and general interest of natural product submissions.

Marceau F, Abe F, Talmadge JE.

Int Immunopharmacol. 2016 Aug;37:3-4. doi: 10.1016/j.intimp.2015.11.038. Epub 2015 Dec 8. No abstract available.

PMID:
26674722
18.

Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models.

Parks A, Charest-Morin X, Boivin-Welch M, Bouthillier J, Marceau F.

PeerJ. 2015 Oct 6;3:e1314. doi: 10.7717/peerj.1314. eCollection 2015.

19.

Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Charest-Morin X, Raghavan A, Charles ML, Kolodka T, Bouthillier J, Jean M, Robbins MS, Marceau F.

Pharmacol Res Perspect. 2015 Mar;3(2):e00119. doi: 10.1002/prp2.119. Epub 2015 Feb 10.

20.

Pharmacological profile of a bifunctional ligand of the formyl peptide receptor1 fused to the myc epitope.

Charest-Morin X, Roy C, Fernandes MJ, Marceau F.

Int Immunopharmacol. 2015 Mar;25(1):229-34. doi: 10.1016/j.intimp.2015.01.029. Epub 2015 Feb 10.

21.

A tagged parathyroid hormone derivative as a carrier of antibody cargoes transported by the G protein coupled PTH1 receptor.

Charest-Morin X, Fortin JP, Lodge R, Allaeys I, Poubelle PE, Marceau F.

Peptides. 2014 Oct;60:71-9. doi: 10.1016/j.peptides.2014.08.001. Epub 2014 Aug 12.

PMID:
25128082
22.

Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists.

Charest-Morin X, Roy C, Fortin EJ, Bouthillier J, Marceau F.

Front Pharmacol. 2014 Mar 7;5:32. doi: 10.3389/fphar.2014.00032. eCollection 2014.

23.

NLRP3 promotes autophagy of urate crystals phagocytized by human osteoblasts.

Allaeys I, Marceau F, Poubelle PE.

Arthritis Res Ther. 2013 Nov 1;15(6):R176. doi: 10.1186/ar4365.

24.

Assessment of cation trapping by cellular acidic compartments.

Marceau F, Roy C, Bouthillier J.

Methods Enzymol. 2014;534:119-31. doi: 10.1016/B978-0-12-397926-1.00007-X.

PMID:
24359951
25.
26.

C-C chemokine receptor-7 mediated endocytosis of antibody cargoes into intact cells.

Charest-Morin X, Pépin R, Gagné-Henley A, Morissette G, Lodge R, Marceau F.

Front Pharmacol. 2013 Sep 24;4:122. doi: 10.3389/fphar.2013.00122. eCollection 2013.

27.

Vasopeptidase-activated latent ligands of the histamine receptor-1.

Gera L, Roy C, Charest-Morin X, Marceau F.

Int Immunopharmacol. 2013 Nov;17(3):677-83. doi: 10.1016/j.intimp.2013.08.014. Epub 2013 Sep 7.

28.
29.

Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.

Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, Gaudreault RC, Marceau F.

Pharmacol Res. 2013 May;71:44-52. doi: 10.1016/j.phrs.2013.02.007. Epub 2013 Feb 27.

30.

Bifunctional epitope-agonist ligands of the bradykinin B(2) receptor.

Gera L, Roy C, Marceau F.

Biol Chem. 2013 Mar;394(3):379-83. doi: 10.1515/hsz-2012-0286.

31.
32.

Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs.

Marceau F, Bawolak MT, Lodge R, Bouthillier J, Gagné-Henley A, Gaudreault RC, Morissette G.

Toxicol Appl Pharmacol. 2012 Feb 15;259(1):1-12. doi: 10.1016/j.taap.2011.12.004. Epub 2011 Dec 13. Review.

33.

Prolonged signalling and trafficking of the bradykinin B2 receptor stimulated with the amphibian peptide maximakinin: insight into the endosomal inactivation of kinins.

Bawolak MT, Roy C, Gera L, Marceau F.

Pharmacol Res. 2012 Feb;65(2):247-53. doi: 10.1016/j.phrs.2011.11.004. Epub 2011 Nov 16.

34.

An in vitro reconstitution system to address the mechanism of the vascular expression of the bradykinin B₁ receptor in response to angiotensin converting enzyme inhibition.

Roy C, Marceau E, Gera L, Marceau F.

Vascul Pharmacol. 2012 Aug 19;57(1):15-23. doi: 10.1016/j.vph.2011.09.003. Epub 2011 Oct 2.

35.

Met-Lys-bradykinin-Ser-Ser, a peptide produced by the neutrophil from kininogen, is metabolically activated by angiotensin converting enzyme in vascular tissue.

Gera L, Roy C, Bawolak MT, Bouthillier J, Adam A, Marceau F.

Pharmacol Res. 2011 Nov;64(5):528-34. doi: 10.1016/j.phrs.2011.08.001. Epub 2011 Aug 11.

36.

Dissociation of the vacuolar and macroautophagic cytopathology from the cytotoxicity induced by the lipophilic local anesthetic bupivacaine.

Morissette G, Bawolak MT, Marceau F.

Can J Physiol Pharmacol. 2011 Jul;89(7):505-12. doi: 10.1139/Y11-056.

PMID:
21812528
37.

Bradykinin B₂ receptor-mediated transport into intact cells: anti-receptor antibody-based cargoes.

Bawolak MT, Lodge R, Morissette G, Marceau F.

Eur J Pharmacol. 2011 Oct 1;668(1-2):107-14. doi: 10.1016/j.ejphar.2011.06.041. Epub 2011 Jul 7.

PMID:
21756898
38.

Design of fluorescent bradykinin analogs: application to imaging of B2 receptor-mediated agonist endocytosis and trafficking and angiotensin-converting enzyme.

Gera L, Bawolak MT, Roy C, Lodge R, Marceau F.

J Pharmacol Exp Ther. 2011 Apr;337(1):33-41. doi: 10.1124/jpet.110.177147. Epub 2011 Jan 4.

PMID:
21205920
39.

Vascular smooth muscle contractility assays for inflammatory and immunological mediators.

Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J.

Int Immunopharmacol. 2010 Nov;10(11):1344-53. doi: 10.1016/j.intimp.2010.08.016. Epub 2010 Sep 8. Review.

40.

Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells.

Koumbadinga GA, Désormeaux A, Adam A, Marceau F.

Eur J Pharmacol. 2010 Nov 25;647(1-3):117-25. doi: 10.1016/j.ejphar.2010.08.008. Epub 2010 Sep 4.

41.

A ligand-based approach to investigate the expression and function of angiotensin converting enzyme in intact human umbilical vein endothelial cells.

Koumbadinga GA, Bawolak MT, Marceau E, Adam A, Gera L, Marceau F.

Peptides. 2010 Aug;31(8):1546-54. doi: 10.1016/j.peptides.2010.04.027. Epub 2010 May 7.

42.

Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.

Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B.

Biomaterials. 2010 Aug;31(22):5741-8. doi: 10.1016/j.biomaterials.2010.03.074. Epub 2010 Apr 27.

43.

Vacuolar ATPase-mediated sequestration of local anesthetics in swollen macroautophagosomes.

Bawolak MT, Morissette G, Marceau F.

Can J Anaesth. 2010 Mar;57(3):230-9. doi: 10.1007/s12630-009-9220-9. Epub 2010 Jan 7.

PMID:
20054683
44.

Guest editorial for the special issue peptide receptors: focus on neuropeptides and kinins.

Marceau F, Quirion R.

Neuropeptides. 2010 Apr;44(2):65-7. doi: 10.1016/j.npep.2009.09.001. Epub 2009 Oct 20. No abstract available.

PMID:
19846219
45.

Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.

Adam A, Leclair P, Montpas N, Koumbadinga GA, Bachelard H, Marceau F.

Neuropeptides. 2010 Apr;44(2):69-75. doi: 10.1016/j.npep.2009.09.004.

46.

Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way.

Brousseau C, Morissette G, Fortin JP, Marceau F, Petitclerc E.

Can J Physiol Pharmacol. 2009 Sep;87(9):694-701. doi: 10.1139/y09-063.

PMID:
19794520
47.

Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B(2) receptors.

Bawolak MT, Fortin S, Bouthillier J, Adam A, Gera L, C-Gaudreault R, Marceau F.

Br J Pharmacol. 2009 Nov;158(5):1375-86. doi: 10.1111/j.1476-5381.2009.00409.x. Epub 2009 Sep 28.

48.

Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: a model for the distribution of lipophilic cationic drugs to autophagic vacuoles.

Marceau F, Bawolak MT, Bouthillier J, Morissette G.

Drug Metab Dispos. 2009 Dec;37(12):2271-4. doi: 10.1124/dmd.109.028480. Epub 2009 Sep 22.

PMID:
19773536
49.

Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors.

Hoover T, Lippmann M, Grouzmann E, Marceau F, Herscu P.

Clin Exp Allergy. 2010 Jan;40(1):50-61. doi: 10.1111/j.1365-2222.2009.03323.x. Epub 2009 Jul 29. Review.

PMID:
19659669
50.

NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse.

Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orléans-Juste P, Marceau F, Thorin E, Sévigny J.

Cardiovasc Res. 2010 Jan 1;85(1):204-13. doi: 10.1093/cvr/cvp265.

Supplemental Content

Loading ...
Support Center